095700.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
今日成交量	60 946.00
平均成交量	217 744
市值	318.33B
EPS	KRW0 ( 2024-02-08 )
下一个收益日期	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW12.30 (0.16%)

音量相关性

長: -0.10 (neutral)

短: 0.37 (neutral)

Signal:(55.461) Neutral

Genexine, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Genexine, Inc. 相关性 - 货币/商品

-0.60
( weak negative )

-0.50
( neutral )

-0.03
( neutral )

0.01
( neutral )

0.33
( neutral )

Genexine, Inc. 财务报表

Annual	2023
营收:	KRW4.43B
毛利润:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2023
营收:	KRW4.43B
毛利润:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2022
营收:	KRW16.14B
毛利润:	KRW7.30B (45.26 %)
EPS:	KRW-1 326.23

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.